This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drugdevelopment is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.
There are so many different types of careers within the field of pharmacy—from research and drugdevelopment to pharmacy informatics! Another unique aspect of this model is that all interprofessional team members can access and document within a universal electronic medicalrecord (EPIC).
Therefore, to help contextualise study findings, external comparator arms (ECAs) can be employed, which compile data from external sources, such as patient registries and other medicalrecords. In the general case, RCTs are the optimal approach to clinical research and drugdevelopment. Discussion.
Two weeks ago, FDA published a draft of its latest drugdevelopment guidance explaining how drug and biological product developers can use this pathway to meet the statutory standard for efficacy. the Confirmatory Evidence Guidance, available here ) had appeared on CDER’s Guidance Agenda for the past three years.
If appropriately implemented, blockchain-based medicalrecords systems of tomorrow could be far more accurate, secure and accessible than the one-size-fits-all approach applied to today’s electronic health records, all while putting additional power back in the hands of the patients. The state of medicalrecords today.
Artificial intelligence (AI) is set to be the most disruptive emerging technology in drugdevelopment in 2023, unlocking advanced analytics, enabling automation, and increasing speed across the clinical trial value chain. AI can also alert medical staff and patients to clinical trial opportunities.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content